首页> 美国卫生研究院文献>other >Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)
【2h】

Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)

机译:新型的咪唑并嘧啶酮和二氢咪唑并嘧啶酮作为代谢型谷氨酸受体5(mGlu5)的正构构调节剂的发现和SAR

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We report the discovery and SAR of two novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs). Exploration of several structural features in the western and eastern part of the imidazopyrimidinone core and combinations thereof, revealed compound >4a as a mGlu5 PAM with good in vitro potency and efficacy, acceptable drug metabolism and pharmacokinetic (DMPK) properties and in vivo efficacy in an amphetamine-based model of psychosis. However, the presence of CNS-mediated adverse effects in preclinical species precluded any further in vivo evaluation.
机译:我们报告发现和SAR的两个新系列的咪唑并嘧啶和二氢咪唑并嘧啶作为代谢型谷氨酸受体5(mGlu5)变构调节剂(PAMs)。探索咪唑并嘧啶酮核心的西部和东部的若干结构特征及其组合,发现化合物> 4a 作为mGlu5 PAM,具有良好的体外效能和功效,可接受的药物代谢和药代动力学(DMPK)特性和基于苯丙胺的精神病模型的体内功效。但是,临床前物种中CNS介导的不良反应的存在排除了任何进一步的体内评估。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号